spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  uveitis 

 HSMN NewsFeed - 23 Sep 2024
UCB Announces U.S. FDA Approvals for BIMZELX(R) (bimekizumab-bkzx) for the Treatment of Psoriatic Arthritis, Non-Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Mar 2024
Mallinckrodt Announces U.S. FDA Approval of Supplemental New Drug Application for Acthar(R) Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect(TM) Injector
Devices Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 12 Feb 2024
AbbVie Completes Acquisition of ImmunoGen
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 23 Feb 2021
PYC Therapeutics Expands U.S. Executive Leadership Team with the Appointment of Glenn Noronha, PhD, as Chief Development Officer
Biopharmaceutical Drug Delivery Personnel
 HSMN NewsFeed - 11 Dec 2020
BAVENCIO(R) (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Nov 2020
Innovent Announces NMPA Granted New Indication Approval for SULINNO(R) (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Sep 2020
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Jul 2020
Interim Six-Month Data of RPGR Gene Therapy Shows Significant Vision Improvement in Patients Living with X-Linked Retinitis Pigmentosa
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 9 Apr 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2019
Bausch Health Licenses Clearside Biomedical's XIPERE(TM) (Triamcinolone Acetonide Suprachoroidal Injectable Suspension), An Investigational Treatment For Macular Edema Associated With Uveitis
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Jun 2019
Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 27 Mar 2019
Novartis receives FDA approval for Mayzent(R) (siponimod), the first oral drug to treat secondary progressive MS with active disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 26 Mar 2019
Aldeyra Therapeutics Announces Positive Top-Line Results from the Phase 3 ALLEVIATE Trial in Patients with Allergic Conjunctivitis
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 29 Jan 2019
Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
Biopharmaceuticals Ophthalmology Mergers & Acquisitions
 HSMN NewsFeed - 19 Nov 2018
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Aug 2018
Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI(TM) in combination with MEKTOVI(R) and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Jul 2018
The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI(TM) (encorafenib) in Combination with MEKTOVI(R) (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2018
Mallinckrodt Reports Interim Findings Of H.P. Acthar(R) Gel (Repository Corticotropin Injection) Studies
Biopharmaceuticals
 HSMN NewsFeed - 16 Apr 2018
Apitope Announces Positive Results with Novel Treatment for Graves' Disease
Biopharmaceuticals
 HSMN NewsFeed - 14 Feb 2018
Phase II Data Support Potential for Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, for People With Diabetic Macular Edema
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 4 Jan 2018
Oculis Raises CHF20 Million in a Series B Financing Round to Advance Breakthrough Treatments for Ophthalmic Diseases
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 21 Dec 2017
Santen Receives Complete Response Letter from U.S. FDA for Intravitreal Sirolimus (DE-109)
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 18 Dec 2017
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 12 Dec 2017
Eyevensys Appoints Dr. Patricia Zilliox as Chief Executive Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Sep 2017
Eyevensys Appoints Dr Ronald R. Buggage as Chief Medical Officer
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Mar 2017
U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA(R) (adalimumab) Prescribing Information
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Mar 2017
FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA Product Launch
 HSMN NewsFeed - 21 Mar 2017
Eyevensys Appoints Leading Life Sciences Executive and Ophthalmology Expert Dr. Garth Cumberlidge as Chairman
Biopharmaceuticals Devices Ophthalmology Personnel
 HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Feb 2017
Valeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Nov 2016
AbbVie's HUMIRA(R) (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Sep 2016
Eyevensys Announces Series A Extension Bringing Total Capital Raised to €9 Million
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 2 Aug 2016
pSivida Corp and Hospital for Special Surgery Innovation Center Announce Opening of IND for Sustained-Release Implant for Severe Knee Osteoarthritis
Devices Drug Delivery Orthopaedic
 HSMN NewsFeed - 27 May 2016
AbbVie's HUMIRA(R) (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Dec 2015
Clearside Biomedical, Inc. Completes $20 Million Series C Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Apr 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Nov 2014
Eleven Biotherapeutics Announces Additional Financing of $20 Million
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 29 Sep 2014
Allergan Announces FDA Approves Revised Indication for OZURDEX(R) (dexamethasone intravitreal implant) 0.7 mg for the Treatment of Diabetic Macular Edema
Biopharmaceuticals Ophthalmology Drug Delivery FDA
 HSMN NewsFeed - 30 Jun 2014
Allergan Announces R&D Pipeline Update and U.S. FDA Approval; Company to Host Conference Call Today, Monday, June 30th at 10:30 AM ET
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 31 Dec 2013
OphthaliX to Conduct a Retrospective Analysis of the Phase III Dry Eye Syndrome Study Data Based on the A3 Adenosine Receptor Biomarker
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 30 Dec 2013
OphthaliX Announces Top-Line Results of Phase III Study with CF101 for Dry Eye Syndrome
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 19 Sep 2013
Neurotech Pharmaceuticals Adds Ophthalmic Leaders to Advance Groundbreaking Sight-Saving Therapies
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 6 Aug 2013
James Mazzo Appointed Executive Chairman of Neurotech Pharmaceuticals
Biopharmaceuticals Drug Delivery Ophthalmology Personnel
 HSMN NewsFeed - 4 Mar 2013
Clearside Biomedical, Inc. Names Stephen H. Lang Vice President, Commercial Operations
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 27 Dec 2012
Isotechnika Announces That Lux Biosciences' Phase 3 Uveitis Study Did Not Meet Primary Endpoint
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 12 Dec 2012
Sucampo Announces FDA Approval of an sNDA for RESCULA(R) (unoprostone isopropyl)
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 21 Dec 2011
Denali Concrete Management Inc. Announces the Commencement of Patient Enrollment for the Phase 3 Dry Eye Syndrome Study
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 7 Dec 2011
Icon Appoints Murahashi Vice President, Clinical Development
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 7 Jun 2011
XOMA Appoints Paul Rubin, M.D. as Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2011
Novartis Therapy Gilenya Reduced the Risk of MS Disability Progression Regardless of Treatment History or Disease Severity, New Analysis Shows
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Jan 2011
EyeGate Pharma Secures Additional $5.9M Series D Venture Funding
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 15 Oct 2010
FDA Approves H.P. Acthar(R) Gel for the Treatment of Infantile Spasms
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 22 Sep 2010
Novartis gains FDA approval for Gilenya, a novel first-line multiple sclerosis treatment shown to significantly reduce relapses and delay disability progression
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 31 Aug 2010
Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 26 Aug 2010
XOMA Appoints Jack L. Wyszomierski to Its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2010
Lux Biosciences Names Dean Mitchell President and CEO
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 29 Apr 2010
EyeGate Pharma Establishes Research Collaboration With GlaxoSmithKline to Deliver Medicines Using the EyeGate(R) II Delivery System
Devices Biopharmaceuticals Drug Delivery Ophthalmology
 HSMN NewsFeed - 8 Jan 2010
EyeGate Pharma Secures $22M in Series D Venture Funding for Continued Development of EGP-437 for Dry Eye Syndrome
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 21 Oct 2009
MacuSight(R) Receives Fast Track Designation From FDA for Perceiva(TM) in Treatment of Diabetic Macular Edema
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 19 Oct 2009
Lux Biosciences Completes $50 Million Series B Financing
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 16 Sep 2009
Sirion Therapeutics Announces FDA Approval of Zirgan(TM) (Ganciclovir Ophthalmic Gel) 0.15% for Herpetic Keratitis
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 16 Feb 2009
Sirion Therapeutics Partners With Advanced Vision Research (TheraTears(R)) to Promote Products for Retinal and Meibomian Gland Health
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 2 Feb 2009
pSivida Corp. Names Paul Ashton, Ph.D. President and Chief Executive Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 26 Jan 2009
Sirion Therapeutics New Drug Application for Ganciclovir is Accepted for Review by the FDA for the Treatment of Ocular Herpes
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 22 Jan 2009
Isotechnika Announces Full Enrollment Achieved in Partner Atrium's CONFIRM 1 Trial for Voclosporin Coated Coronary Stent System
Devices Interventional Cardiology
 HSMN NewsFeed - 9 Jan 2009
EyeGate Pharma Receives Orphan Drug Designation for Corneal Graft Rejection From U.S. FDA
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 19 Aug 2008
Regeneron and Bayer HealthCare Announce VEGF Trap-Eye Achieved Durable Improvement in Vision over 52 Weeks in a Phase 2 Study in Patients with Age-Related Macular Degeneration
Biopharmaceuticals Opthalmology
 HSMN NewsFeed - 16 Jul 2008
Peptimmune Announces the Second Close of Series D Private Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Jun 2008
Sirion Therapeutics Announces FDA Approval of Durezol(TM) for Treatment of Postoperative Ocular Inflammation and Pain
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 16 Jun 2008
Allergan Receives U.S. Food and Drug Administration Approval for TRIVARIS(TM) (triamcinolone acetonide injectable suspension) 80 mg/mL
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 16 Jun 2008
EyeGate Pharma Appoints Amy Cohen as Vice President, Clinical Operations
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 10 Jun 2008
Merrimack Pharmaceuticals Raises $60 Million in Private Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 9 Jun 2008
EyeGate Pharma Adds Drug Development and Delivery Expert, Praveen Tyle, to Its Board of Directors
Biopharmaceuticals Ophthalmology Drug Delivery Personnel
 HSMN NewsFeed - 29 May 2008
Drug-Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical Trials
Devices Interventional Cardiology
 HSMN NewsFeed - 28 Apr 2008
Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular Degeneration
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Apr 2008
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Mar 2008
EyeGate Pharma Secures $15M in Series C Venture Funding
Biopharmaceuticals Ophthalmology Venture Capital
 HSMN NewsFeed - 30 Jan 2008
Lux Granted Fast Track Designation for LX201 for Corneal Transplant Rejection
Biopharmaceuticals Ophthalmology Drug Delivery FDA
 HSMN NewsFeed - 23 Jan 2008
EyeGate Pharma Appoints Michael A. Patane to Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jan 2008
Peptimmune Announces First Close of Series D Private Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 20 Dec 2007
EyeGate Pharma Appoints Remis Bistras as Vice President, Business Development
Devices Drug Delivery Personnel
 HSMN NewsFeed - 8 Nov 2007
Abbott Study Examines Rates of Uveitis (Inflammation of the Eye) in Ankylosing Spondylitis Patients Treated with HUMIRA(R) (adalimumab)
Biopharmaceuticals
 HSMN NewsFeed - 25 Oct 2007
Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 10 Oct 2007
Isotechnika Inc. appoints two new senior company officers
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Sep 2007
Isotechnika Inc. announces senior management changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Aug 2007
Lux Granted Fast Track Designation by FDA for LX211 for the Treatment of Uveitis
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 31 Jul 2007
EMEA Committee for Orphan Medicinal Products Recommends Orphan Medicinal Product Designation for Lux Biosciences' LX211 for the Treatment of Uveitis
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 25 Jul 2007
EyeGate Pharma Announces Executive Appointments
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 23 Jul 2007
Merrimack Pharmaceuticals Names William Slichenmyer, M.D. Senior Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jul 2007
pSivida Strengthens its Position in Drug Delivery Sector
Biopharmaceuticals Drug Delivery Ophthalmology
 HSMN NewsFeed - 26 Jun 2007
Merrimack Pharmaceuticals Names Lisa Evren Senior Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jun 2007
Enzo Life Sciences, Inc., Completes Acquisition of Axxora Life Sciences, Inc.
Diagnostics Mergers & Acquisitions
 HSMN NewsFeed - 22 May 2007
Enzo Biochem Individualized Oral Immune Regulation Therapy May Be Effective Approach to Treating Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 3 May 2007
Enzo Biochem Announces Supply and Royalty Bearing Cross-Licensing Agreements with Abbott
Diagnostics Licensing
 HSMN NewsFeed - 1 May 2007
pSivida Announces Board Change
Biopharmaceuticals Ophthalmology Drug Delivery Personnel
 HSMN NewsFeed - 17 Apr 2007
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 4 Apr 2007
pSivida Signs $165 Million(US) Collaborative Research and Licensing Agreement with Pfizer
Biopharmaceuticals Ophthalmology Drug Delivery Licensing
 HSMN NewsFeed - 29 Jan 2007
pSivida Announcement: RetisertTM Drug Implant Receives Product Specific Bill Code and Medicare Reimbursement Rate
Biopharmaceuticals Ophthalmology Reimbursement
 HSMN NewsFeed - 24 Jan 2007
pSivida appoints Boston based Managing Director
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 17 Jan 2007
Sirion Therapeutics Acquires U.S. License to Develop New Treatment for Viral Eye Infection
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 17 Jan 2007
EyeGate Pharma Closes $12M Series B Venture Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 15 Jan 2007
Lux Biosciences Receives Orphan Drug Designation from the FDA for Two Ophthalmic Products
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 26 Dec 2006
pSivida Enters Licensing Negotiations with Major Global Pharma for Drug Delivery Technologies
Biopharmaceuticals Drug Delivery Licensing
 HSMN NewsFeed - 30 Nov 2006
U.S. Court of Appeals Allows Enzo Biochem Patent Infringement Suit to Proceed
Diagnostics Litigation
 HSMN NewsFeed - 28 Nov 2006
Lux Biosciences Receives FDA Clearance for LX211 IND
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 7 Nov 2006
Lux Biosciences Announces Exclusive Worldwide License Agreement with NIH for Late Stage Ophthalmic Product
Devices Licensing Ophthalmology
 HSMN NewsFeed - 30 Oct 2006
EyeGate Pharma Starts U.S. Operations in Waltham, MA
Biopharmaceuticals Ophthalmology Personnel
 HSMN NewsFeed - 16 Oct 2006
Enzo Biochem Appoints Gary C. Cupit, Former Novartis Pharmaceutical Executive, President of Enzo Therapeutics Unit
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Oct 2006
First Patient Implanted in pSivida European Pancreatic Cancer Study
Devices Oncology
 HSMN NewsFeed - 22 Jun 2006
Sirion Therapeutics Acquires U.S. License to Develop New Treatment for Eye Disease
Biopharmaceuticals Ophthalmology Licensing
 HSMN NewsFeed - 25 May 2006
Lux Biosciences Raises $36 Million in Series A Financing and Signs Agreement for Advanced Clinical Stage Product
Biopharmaceuticals Venture Capital Licensing
 HSMN NewsFeed - 25 May 2006
pSivida Provides Update on BrachySil(TM) Liver Program: Expansion of Multicenter Clinical Trial
Biopharmacetuicals Oncology Drug Delivery
 HSMN NewsFeed - 25 May 2006
Isotechnika signs agreement granting Lux Biosciences Worldwide Ophthalmic rights to ISA247
Biopharmaceuticals Licensing
Return to NewsFeed  

 Additional items found! 28

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 28 additional stories matching:
uveitis
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.